Ascendis Pharma Earnings Estimate
| ASND Stock | USD 165.00 12.02 7.86% |
Ascendis |
Ascendis Pharma Earnings Estimation Breakdown
The calculation of Ascendis Pharma's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Ascendis Pharma is estimated to be -1.5065 with the future projection ranging from a low of -1.9548 to a high of -1.05. Please be aware that this consensus of annual earnings estimates for Ascendis Pharma AS is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.95 Lowest | Expected EPS | -1.05 Highest |
Ascendis Pharma Earnings Projection Consensus
Suppose the current estimates of Ascendis Pharma's value are higher than the current market price of the Ascendis Pharma stock. In this case, investors may conclude that Ascendis Pharma is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Ascendis Pharma's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 15 | 73.38% | -0.64 | -1.5065 | -7.11 |
Ascendis Pharma Earnings History
Earnings estimate consensus by Ascendis Pharma AS analysts from Wall Street is used by the market to judge Ascendis Pharma's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Ascendis Pharma's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Ascendis Pharma Quarterly Gross Profit |
|
Ascendis Pharma Earnings per Share Projection vs Actual
Actual Earning per Share of Ascendis Pharma refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Ascendis Pharma AS predict the company's earnings will be in the future. The higher the earnings per share of Ascendis Pharma, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Ascendis Pharma Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Ascendis Pharma, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Ascendis Pharma should always be considered in relation to other companies to make a more educated investment decision.Ascendis Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Ascendis Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-13 | 2024-12-31 | -0.9327 | -0.64 | 0.2927 | 31 | ||
2024-11-05 | 2024-09-30 | -1.89 | -1.72 | 0.17 | 8 | ||
2024-09-03 | 2024-06-30 | -1.46 | -2.11 | -0.65 | 44 | ||
2024-05-02 | 2024-03-31 | -1.5 | -2.3 | -0.8 | 53 | ||
2024-02-07 | 2023-12-31 | -2.03 | -1.54 | 0.49 | 24 | ||
2023-11-07 | 2023-09-30 | -2.38 | -2.88 | -0.5 | 21 | ||
2023-09-05 | 2023-06-30 | -2.59 | -2.16 | 0.43 | 16 | ||
2023-04-27 | 2023-03-31 | -2.66 | -1.98 | 0.68 | 25 | ||
2023-02-16 | 2022-12-31 | -2.56 | -3.7 | -1.14 | 44 | ||
2022-11-02 | 2022-09-30 | -2.49 | -3.03 | -0.54 | 21 | ||
2022-08-10 | 2022-06-30 | -2.13 | -1.46 | 0.67 | 31 | ||
2022-05-11 | 2022-03-31 | -2 | -2.21 | -0.21 | 10 | ||
2022-03-02 | 2021-12-31 | -2.34 | -1.87 | 0.47 | 20 | ||
2021-11-10 | 2021-09-30 | -2.29 | -1.47 | 0.82 | 35 | ||
2021-08-25 | 2021-06-30 | -2.23 | -2.5 | -0.27 | 12 | ||
2021-05-27 | 2021-03-31 | -1.71 | -1.17 | 0.54 | 31 | ||
2021-03-10 | 2020-12-31 | -1.55 | -2.64 | -1.09 | 70 | ||
2020-11-11 | 2020-09-30 | -1.58 | -2.31 | -0.73 | 46 | ||
2020-08-27 | 2020-06-30 | -1.44 | -1.97 | -0.53 | 36 | ||
2020-05-19 | 2020-03-31 | -1.35 | -1.32 | 0.03 | 2 | ||
2019-12-31 | 2019-12-31 | -1.62 | -1.89 | -0.27 | 16 | ||
2019-11-18 | 2019-09-30 | -1.19 | -0.53 | 0.66 | 55 | ||
2019-08-28 | 2019-06-30 | -1.21 | -1.25 | -0.04 | 3 | ||
2019-05-30 | 2019-03-31 | -1 | -1.24 | -0.24 | 24 | ||
2018-12-31 | 2018-12-31 | -1.14 | -0.86 | 0.28 | 24 | ||
2018-11-28 | 2018-09-30 | -1.07 | -0.81 | 0.26 | 24 | ||
2018-08-29 | 2018-06-30 | -0.9 | -0.55 | 0.35 | 38 | ||
2018-05-30 | 2018-03-31 | -0.77 | -1.07 | -0.3 | 38 | ||
2018-03-28 | 2017-12-31 | -0.8 | -0.92 | -0.12 | 15 | ||
2017-11-16 | 2017-09-30 | -0.74 | -1.04 | -0.3 | 40 | ||
2017-08-18 | 2017-06-30 | -0.72 | -0.94 | -0.22 | 30 | ||
2017-05-23 | 2017-03-31 | -0.75 | -0.83 | -0.08 | 10 | ||
2017-03-22 | 2016-12-31 | -0.62 | -0.67 | -0.05 | 8 | ||
2016-11-30 | 2016-09-30 | -0.68 | -0.8 | -0.12 | 17 | ||
2016-08-31 | 2016-06-30 | -0.69 | -0.6 | 0.09 | 13 | ||
2016-04-14 | 2016-03-31 | -0.46 | -0.54 | -0.08 | 17 | ||
2015-11-12 | 2015-09-30 | -0.6 | -0.33 | 0.27 | 45 | ||
2015-08-24 | 2015-06-30 | -0.49 | -0.7 | -0.21 | 42 | ||
2015-05-18 | 2015-03-31 | -0.39 | 0.07 | 0.46 | 117 | ||
1899-12-31 | 1899-09-30 | -0.76 | -1.07 | -0.31 | 40 |
About Ascendis Pharma Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Ascendis Pharma earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Ascendis Pharma estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Ascendis Pharma fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -2 B | -1.9 B | |
| Earnings Yield | (0.05) | (0.05) | |
| Price Earnings Ratio | (20.16) | (19.16) | |
| Price Earnings To Growth Ratio | 0.88 | 0.92 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascendis Pharma. If investors know Ascendis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascendis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.11) | Revenue Per Share | Quarterly Revenue Growth 0.263 | Return On Assets | Return On Equity |
The market value of Ascendis Pharma AS is measured differently than its book value, which is the value of Ascendis that is recorded on the company's balance sheet. Investors also form their own opinion of Ascendis Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascendis Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascendis Pharma's market value can be influenced by many factors that don't directly affect Ascendis Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascendis Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascendis Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascendis Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.